The Functional Microdomain in Transmembrane Helices 2 and 7 Regulates Expression, Activation, and Coupling Pathways of the Gonadotropin-releasing Hormone Receptor*

(Received for publication, March 10, 1999, and in revised form, July 22, 1999)

Colleen A. Flanagan‡, Wei Zhou§, Ling Chi§, Tony Yuen‡, Vladimir Rodic‡, Derek Robertson‡, Melanie Johnson‡, Pamela Holland‡, Robert P. Millar†††, Harel Weinstein‡‡‡, Rory Mitchell‡‡‡, and Stuart C. Sealfon‡‡‡‡

From the ‡Department of Neurology, the §Fishberg Research Center in Neurobiology and the Departments of ‡‡Biophysics, and ‡‡‡Pharmacology, Mount Sinai School of Medicine, New York, New York 10029, the ‡Medical Research Council Brain Metabolism Unit, 1 George Square, Edinburgh, United Kingdom EH8 9JZ, and the ‡‡Medical Research Council Molecular Reproductive Endocrinology Research Unit, University of Cape Town Medical School, Observatory, 7925 South Africa

Structural microdomains of G protein-coupled receptors (GPCRs) consist of spatially related side chains that mediate discrete functions. The conserved helix 2/helix 7 microdomain was identified because the gonadotropin-releasing hormone (GnRH) receptor appears to have interchanged the Asp3.50 and Asn7.49 residues which are conserved in transmembrane helices 2 and 7 of rhodopsin-like GPCRs. We now demonstrate that different side chains of this microdomain contribute specifically to receptor expression, heterotrimeric G protein-, and small G protein-mediated signaling. An Asn residue is required in position 2.50(87) for expression of the GnRH receptor at the cell surface, most likely through an interaction with the conserved Asn1.30(35) residue, which we also find is required for receptor expression. Most GPCRs require an Asp side chain at either the helix 2 or helix 7 locus of the microdomain for coupling to heterotrimeric G proteins, but the GnRH receptor has transferred the requirement for an acidic residue from helix 2 to 7. However, the presence of Asp at the helix 7 locus precludes small G protein-dependent coupling to phospholipase D. These results implicate specific components of the helix 2/helix 7 microdomain in receptor expression and in determining the ability of the receptor to adopt distinct activated conformations that are optimal for interaction with heterotrimeric and small G proteins.

The gonadotropin-releasing hormone (GnRH)1 receptor be-

logos to the rhodopsin-like family of G protein-coupled receptors (GPCR) (1). This family includes the light-sensitive opsins, protease-activated receptors, and receptors for neurotransmitters, peptides, and glycoproteins. High resolution structural data have not yet been obtained for any GPCR. However, projection maps of rhodopsin, amino acid sequence alignment, and computational modeling indicate that GPCRs have 7 membrane-spanning α-helices (2–6). There is a high degree of homology within the transmembrane helices and certain amino acids are highly conserved throughout the family (2, 3, 7). This diverse family shares the common function of propagating a signal across lipid membranes and the amino acid side chains which are conserved among the GPCRs are likely to constitute key structural motifs which subserve this universal GPCR function.

Several models of GPCRs, including the GnRH receptor (4, 8), have been constructed as aids for investigating receptor structure-function relations. Molecular models of GPCRs can be used to integrate experimental observations and generate structural hypotheses. However, the complexity of these structures and the limited number of experimentally determined constraints can lead to inconsistent behavior of the models (4, 7). To overcome these limitations, we have pursued the approach of identifying discrete structural motifs within receptor models, which might constitute functional microdomains. The microdomains are characterized in detail and subsequently incorporated into whole receptor models. In the GnRH receptor, for example, this approach has recently been used to propose that the motion of the conserved Arg5.50(130) side chain is restricted by interaction with the conserved Asp7.49(138) and the presence of a β-branched, hydrophobic residue, Ile3.54(143) (see “Experimental Procedures” for a description of the amino acid numbering scheme). Incorporation of this microdomain into the whole receptor model suggests that receptor activation is accomplished by repositioning of the Arg5.50(139) side chain, allowing it to interact with the Asp7.49(138) side chain in transmembrane helix 7 (H7) in the activated receptor conformation (4). A related GPCR structural motif consists of this H7 side

cholceystokinin B; ECmax, agonist concentration that produces half-maximal stimulation; Emax, maximum response; GPCR, G protein-coupled receptor; GnRH-A, [d-Ala6,Pro9-NHEt]GnRH; IC50, ligand concentration which inhibits binding of [125I-GnRH-A] by 50%; H, transmembrane helix; IP, inositol phosphate; PLC, phospholipase C; PLD, phospholipase D; PtdBut, phosphatidyl butanol; TRH, thyrotropin releasing hormone; CHAPS, 3-[3-cholamidopropyl]dimethy lammonio]-1-propanesulfonate.

* This work was supported by National Institutes of Health Grants R01 DK 46943 (to S. C. S.) and K05 DA00060 (to H. W.), the South African Medical Research Council, and Fogarty International. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

‡‡‡‡ Current address: MRC Membrane and Adapter Proteins Co-operative Group, Membrane Biology Group, Dept. of Biomedical Sciences, Hugh Robson Bldg., George Square, Edinburgh, EH8 9XD, United Kingdom.

‡‡‡‡‡‡‡‡§§§§ Current address: Medical Research Council Reproductive Biology Unit, 37 Chalmers St., Edinburgh, EH3 9ET, United Kingdom.

||| To whom correspondence should be addressed: Dept. of Neurology, Box 1137, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, New York, NY 10029. Tel.: 212-241-7075; Fax: 212-348-1310; E-mail: sealfon@msvax.mssm.edu.

1 The abbreviations used are: GnRH, gonadotropin-releasing hormone (pGlu-His-Trp-Ser-Tyr-Glu-Leu-Arg-Pro-Gly-NH2); ARF, ADP-ribosylation factor; BFA, brefeldin A; Emax, maximum binding; CCKβ,
chain (usually Asn\textsuperscript{7-19}) and the conserved 2.50 residue (usually Asp) in H2. The H2/H7 microdomain was originally identified from the apparent interchange of these side chains in the GnRH receptor and its functional importance was supported by reciprocal mutagenesis studies (8). Reciprocal mutation experiments in the serotonin 5-HT\textsubscript{2A} (9) thyrotropin releasing hormone (TRH) (10), \mu opioid (11), and NK\textsubscript{1} tachykinin receptors (12) have all shown that the disruption of signal transduction observed with mutation of the Asp\textsuperscript{2.50} side chain in H2 is restored by a second mutation in H7 that interchanges the two conserved residues.

While the inter-related roles of these H2 and H7 side chains in receptor activation (9–12) suggest that they constitute a structural and functional microdomain, this conclusion has been considered controversial (13, 14). The initial study of this microdomain in the GnRH receptor reported that the presence of an Asp residue in both loci eliminated detectable binding. This result raised the possibility that charge repulsion was responsible for the observed phenotype. However, the presence of Asp at both positions in wild-type non-mammalian GnRH receptors (15, 16) and in several other GPCRs (3) as well as in functional mutant GPCRs (9, 10, 14, 17) indicates that the side chains in this microdomain, that are compatible with function, differ among GPCRs.

For a specific receptor, the side chains of the H2/H7 microdomain may contribute to receptor expression and receptor activation and coupling to intracellular signal transduction. The molecular events that underlie receptor activation are a key question in understanding receptor function. Studies of many receptors have implicated the H2/H7 microdomain as a key question in understanding receptor function. Studies of many molecular events that underlie receptor activation are a key function mutant GPCRs (9, 10, 14, 17) indicates that the sidechains of this microdomain, that are compatible with function, differ among GPCRs.

DNA Constructs, Cell Culture, and Transfection—The mutations N2.50(87)D, N2.50(87)Q, N2.50(87)A, D7.49(318)N, D7.49(318)E, and D7.49(318)A were introduced into the mouse GnRH receptor as described previously (8). Thus, Asn\textsuperscript{87}, which is located in the position of the most conserved residue in H2, is designated Asp\textsuperscript{2.50}, while Asp\textsuperscript{18}, which is adjacent to the most conserved residue in H7 (Pro\textsuperscript{7.49}), is designated Asp\textsuperscript{7.49}.

EXPERIMENTAL PROCEDURES

Amino Acid Residue Numbering—To allow comparison of equivalent residues in different GPCRs, amino acids in the transmembrane segments of the GnRH receptor are numbered relative to the most conserved residue of the rhodopsin-like GPCRs, as described previously (7). Thus, Asn\textsuperscript{87}, which is located in the position of the most conserved residue in H2, is designated Asp\textsuperscript{2.50}, while Asp\textsuperscript{18}, which is adjacent to the most conserved residue in H7 (Pro\textsuperscript{7.49}), is designated Asp\textsuperscript{7.49}.

DNA Constructs, Cell Culture, and Transfection—The mutations N2.50(87)D, N2.50(87)Q, N2.50(87)A, D7.49(318)N, D7.49(318)E, and D7.49(318)A were introduced into the mouse GnRH receptor as described previously (8). The altered Sites Mutagenesis System (Promega, Madison, WI), while the mutations N1.50(53)A, N1.50(53)D, N1.50(53)L, and D7.49(318)I were generated using QuikChange (Stratagene, La Jolla, CA). Two epitope tags were applied to the GnRH receptor to allow detection of the receptor by Western blotting. An amino-terminal HA-tag (YPYDVPDYA) was inserted after the initial Met residue of the wild-type GnRH receptor by polymerase chain reaction. Since the mouse GnRH receptor does not have a cytosolic carboxyl-terminal domain, a carboxyl-terminal domain derived from a putative human type II GnRH receptor (20) was appended to allow addition of a carboxyl-terminal heptadecistidine tag using a combination of polymerase chain reaction and mutagenesis subcloning into the pcDNA3 expression vector (Invitrogen, San Diego, CA). The carboxyl-terminal seven amino acids of the carboxyl-terminal domain were substituted with six histidine residues to generate a heptadecistidine tag. All DNA constructs were sequenced to confirm the presence of mutations and epitope tags. COS-1 cells were maintained in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum and transfected as described previously, using LipofectAMINE (Life Technologies Inc., Gaithersburg, MD) (21). Cells were used to intact cell functional assays were seeded into 12- or 24-well plates the day after transfection.

Ligand Binding Assays—[\textsuperscript{3}H]-GnRH-A or GnRH (Bachem, Torrance, CA) was radiolabeled using IO\textsubscript{4}N-2-fluorenylmethoxycarbonyl (FlameTech Co., Rockford, IL). [\textsuperscript{3}H]-GnRH-A was used at a specific activity of 20 Ci/mmol. Whole cell binding assays were performed as described (23). Briefly, transfected cells, in 24-well plates, were incubated for at least 2 h at 4 °C with 125-I-GnRH-A (60,000 cpm/well) and varying concentrations of unlabeled GnRH-A or GnRH (Bachem, Torrance, CA) in a total volume of 0.4 mL/well. The incubation was terminated by removal of the medium and Bound radioactivity was detected using a hexahistidine tag. All DNA constructs were sequenced to confirm the presence of mutations and epitope tags. COS-1 cells were maintained in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum and transfected as described previously, using LipofectAMINE (Life Technologies Inc., Gaithersburg, MD) (21). Cells were used to intact cell functional assays were seeded into 12- or 24-well plates the day after transfection.

For a specific receptor, the side chains of the H2/H7 microdomain may contribute to receptor expression and receptor activation and coupling to intracellular signal transduction. The molecular events that underlie receptor activation are a key question in understanding receptor function. Studies of many receptors have implicated the H2/H7 microdomain as a key question in understanding receptor function. Studies of many molecular events that underlie receptor activation are a key function mutant GPCRs (9, 10, 14, 17) indicates that the sidechains of this microdomain, that are compatible with function, differ among GPCRs.

Multiple Functions of Helix 2 and 7 Microdomain

Membrane binding assays were performed as described previously (24) on some low-expressing constructs because this method makes it possible to increase receptor concentration in the assay by varying the amount of membrane added to incubation tubes. Cell membranes were resuspended in protein-free binding buffer (1 mM EDTA, 10 mM HEPES, pH 7.5) and incubated for 90 min on ice with 125-I-GnRH-A (200,000 cpm), 0.1% bovine serum albumin and varying concentrations of GnRH-A. The reaction was terminated by filtration through GFC filters (Brandel Inc., Gaithersberg, MD) which were presoaked in binding buffer containing 1% bovine serum albumin, and washed twice with binding buffer.

Intracellular Accumulation of cAMP—Transfected cells (9-cm dishes) were washed with phosphate-buffered saline prior to harvesting and homogenization in lysis buffer (50 mM Tris, pH 7.5, 1 mM phenylmethylsulfonyl fluoride, 1 mM EDTA, and 10 μg/ml leupeptin). The homogenate was centrifuged for 10 min at 500 × g for 4 °C and the resulting supernatant was centrifuged at 35,000 × g for 20 min at 4 °C. The membrane pellet was resuspended in lysis buffer (50 mM Tris, pH 7.5, 1 μM NaCl) before incubation overnight in Tetra-His antibody (Qiagen, Valencia, CA, 0.2 μg/ml in blot buffer). Bound antibody was detected using the ECL Western blotting kit (Amersham Pharmacia Biotech).

Phosphatidylidylinositol Hydrolysis—Accumulation of inositol phosphates (IP) in the presence of Li\textsuperscript{+} was determined according to published protocols (25). Transfected cells were labeled for 16 h in Dulbecco’s modified Eagle’s medium containing 0.5 μCi/ml myo-\textsuperscript{3}H)inositol (NEN Life Science Products, North Billerica, MA). After washing with phosphate-buffered saline, the cell pellets were incubated for 20 min at 37 °C with [\textsuperscript{3}H]-inositol (200,000 cpm), 0.1% bovine serum albumin and varying concentrations of GnRH in the presence of 20 mM LiCl. The incubation was terminated by removal of the medium and addition of 10 mM formic acid. [\textsuperscript{3}H]IP was separated from the formic acid extracts on filters (Brandel Inc., Gaithersburg, MD) which were presoaked in binding buffer containing 125-I-GnRH-A (60,000 cpm/well) and varying concentrations of unlabeled GnRH-A or GnRH (Bachem, Torrance, CA) in a total volume of 0.4 mL/well. The incubation was terminated by filtration through GFC filters (Brandel Inc., Gaithersberg, MD) which were presoaked in binding buffer containing 1% bovine serum albumin, and washed twice with binding buffer.

LDL Assay—Activation of PLD was determined by a transphosphatidylolation assay as described previously (26). Transfected cells in 12-well plates were labeled overnight with \textsuperscript{3}H]palmitate in serum-free minimum essential medium. After washing with minimal essential medium containing HEPES (25 mM, pH 7.5) and 1% fatty acid-free bovine serum albumin, cells were preincubated for 30 min at 37 °C with various concentrations of brefeldin A (BFA) in HEPES-buffered minimal essential medium with 0.5% bovine serum albumin, before addition of butan-1-ol (30 mM) and GnRH (1 μM) and incubation for a further 30 min. Reactions were terminated by removal of the medium and addition of 0.5 mL of cold methanol to each well. Phospholipids were extracted and separated on Whatman LK5D thin layer chromatography plates as described (26).

Data Analysis—Kd and Bmax values for binding of GnRH-A were determined using the LIGAND computer program (27). Protein levels were determined by the Lowry method. IC\textsubscript{50} (concentration required for 50% inhibition of 125-I-GnRH-A binding) values for GnRH were estimated using nonlinear curve fitting (KaleidaGraph, Synergy Software, Reading, PA). EC\textsubscript{50} (agonist concentration required for half-maximal response) values for IP production were calculated using KaleidaGraph. IP data were fitted to the equation E = E\textsubscript{max}/(1 + EC\textsubscript{50}/D), where the
Ligand binding parameters were determined from competition binding assays using 125I-GnRH-A as tracer. Data are mean ± S.E. from three to five experiments performed in triplicate. Immunoblotting was performed on epitope-tagged receptor constructs as described under “Experimental Procedures.” The carboxyl-terminal hexahistidine tag was detected with the tetra-His antibody and the relative intensity of the bands is indicated by the number of + signs. IP accumulation was determined in transfected COS-1 cells labeled with myo-[3H]inositol. Data are mean ± S.E. from three to five experiments performed in triplicate. The efficiency of receptor coupling to activation of PLC was calculated from the summarized data in this table using the formula described under “Experimental Procedures” and expressed as a percentage of the wild-type receptor coupling efficiency. ARF-dependent PLD activity was determined as the accumulation of PtdBut in the presence of GnRH (10−6 M) with and without BFA (0.2 mM) and expressed relative to the PtdBut accumulation in the absence of GnRH and BFA.

**RESULTS**

**H2 Mutants Are Not Expressed, but Expression Is Restored in H2/H7 Reciprocal Mutant**—The effects of amino acid substitutions at each locus of the H2/H7 microdomain were studied. The substitutions introduced for Asn2.50(87) (Gln, Asp, and Ala) were designed to test the effects of altered size, charge, and polarity on receptor function. None of the single H2 mutant constructs studied exhibited detectable ligand binding activity, IP accumulation, or ARF-dependent accumulation of phosphatidyl butanol (PtdBut) (Table I).

To determine whether the lack of ligand binding by the H2 mutants resulted from altered receptor expression, we utilized an immunoblot assay of epitope-tagged receptor constructs. The parent epitope-tagged construct had an amino-terminal HA-tag and a carboxyl-terminal domain with a hexahistidine tag (see “Experimental Procedures”). The effects of epitope tagging on receptor function were evaluated. All H2 and H7 mutant constructs were epitope-tagged and tested in ligand binding and IP accumulation assays. The tagged wild-type and mutant receptors mediated IP accumulation with EC50 values which were comparable to those of corresponding untagged receptors. For all constructs with measurable ligand binding, Kd values were unchanged and Bmax values elevated with epitope tagging. As was observed for the untagged receptors, ligand binding was not detectable in the epitope-tagged N2.50(87)D and N2.50(87)A constructs (Table II). The epitope-tagged N2.50(87)Q construct exhibited low, but measurable ligand binding (Table II). This tagged construct also mediated a low level of GnRH-stimulated IP accumulation (not shown). The relative receptor expression, as measured by ligand binding, and the function of the tagged receptors closely paralleled that of the untagged receptors, thus validating the use of the tagged receptors in protein expression assays.

Western blots of the epitope-tagged wild-type receptor yielded a broad band of 55–85 kDa (not shown) which was compressed to a single band at 34 kDa after deglycosylation (Fig. 1). This pattern resembles that reported for the photoaffinity-labeled GnRH receptor (28). To increase sensitivity of detection and facilitate comparison of band intensity, all receptors were deglycosylated prior to immunoblot analysis. At a protein concentration of 48 μg/ml was used for ligand binding and IP accumulation assays. The tagged wild-type and mutant GnRH receptors were incubated with 125I-GnRH-A (200,000 cpm) and increasing concentrations of unlabeled GnRH-A. Membrane protein concentrations ranged from 48 to 62 μg/ml for wild-type receptors, while 400–900 μg/ml was used for cells transfected with H2 mutant receptors and vector to enhance the sensitivity of receptor detection. The low binding of the mutant receptors prevents reliable calculation of Bmax values, thus maximum specific binding is reported to indicate relative expression levels.

| Construct | Maximum specific binding | IC50, GnRH-A |
|-----------|--------------------------|--------------|
| Wild type | 86.5 ± 10.9 | 0.91 ± 0.05 |
| Tagged wild type | 226.3 ± 27.3 | 1.06 ± 0.09 |
| Tagged N2.50(87)D | 1.78 ± 0.08 | 1.06 ± 0.09 |
| Tagged N2.50(87)Q | 9.3 ± 2.2 | 1.23 ± 0.03 |
| Tagged N2.50(87)A | 0.65 ± 0.25 | 0.38 ± 0.44 |

**TABLE I**

| Construct | Bmax | Kd, GnRH-A | IC50, GnRH | Immunoblot | IP accumulation | Coupling efficiency | PtdBut, maximum BFA-inhibitable |
|-----------|------|------------|------------|------------|----------------|-------------------|-------------------------------|
| Wild-type | 582 ± 135 | 1.2 ± 0.6 | 20 ± 15 | ++ + | 100 | 0.85 ± 0.46 | 100 | -1.6 ± 1.5 |
| N2.50(87)D | Und | Und | Und | ++ | -1.5 ± 0.7 | -0.4 ± 0.5 |
| N2.50(87)Q | Und | Und | Und | - | 2.2 ± 0.7 | -0.4 ± 0.4 |
| N2.50(87)A | Und | Und | Und | - | 0.1 ± 0.5 | 0.1 ± 0.4 |
| N2.50(87)D | 170 ± 46 | 1.3 ± 0.7 | 32 ± 20 | +++ | 11.7 ± 4.5 | 30 ± 18 | 3.3 | 3.2 ± 0.6 |
| D7.49(318)N | 386 ± 42 | 0.97 ± 0.23 | 27 ± 18 | +++ | 38.9 ± 11.7 | 45 ± 29 | 3.8 | 4.7 ± 0.6 |
| D7.49(318)E | 30 ± 3 | 2.3 ± 1.4 | 33 ± 7 | ++ | 36.6 ± 6.5 | 20 ± 10 | 76.7 | 0.3 ± 1.0 |
| D7.49(318)A | 610 ± 156 | 0.71 ± 0.22 | 22 ± 14 | +++ | 12.0 ± 0.1 | 42 ± 18 | 0.7 | 0.1 ± 0.7 |
| D7.49(318)L | Und | Und | Und | + | 3.6 ± 0.2 | 4.3 ± 3.3 | 0.23 | 0.16 |
| N1.50(53)D | Und | Und | Und | + | 4.3 ± 4.1 | 4.3 ± 4.1 | 0.02 | 0.05 |
| N1.50(53)A | Und | Und | Und | + | 8.5 ± 1.6 | 8.5 ± 1.6 | 0.02 | 0.05 |
| N1.50(53)D | Und | Und | Und | + | 1.6 ± | 1.6 ± | 0.02 | 0.05 |

* Constructs in which total binding was too low to estimate Bmax are reported as undetectable.

**TABLE II**

| Construct | Maximum specific binding | IC50, GnRH-A |
|-----------|--------------------------|--------------|
| Wild type | 86.5 ± 10.9 | 0.91 ± 0.05 |
| Tagged wild type | 226.3 ± 27.3 | 1.06 ± 0.09 |
| Tagged N2.50(87)D | 1.78 ± 0.08 | 1.06 ± 0.09 |
| Tagged N2.50(87)Q | 9.3 ± 2.2 | 1.23 ± 0.03 |
| Tagged N2.50(87)A | 0.65 ± 0.25 | 0.38 ± 0.44 |

**Multiple Functions of Helix 2 and 7 Microdomain**

**E** is the maximum IP accumulation and D is the concentration of the agonist. Transient transfection of the wild-type GnRH receptor into COS-1 cells leads to expression of an appreciable level of “spare receptor” which results in an EC50 for IP accumulation that is significantly lower than the Kd for GnRH binding to the receptor (21). Because of the receptor reserve in the wild-type receptor and the varied expression levels of the mutant receptors, simple comparison of maximal IP accumulation does not yield an accurate measure of how well a particular receptor is activated. To facilitate comparison of receptor activation, we utilized a previously derived expression of receptor coupling efficiency, Q, which is defined as: Q = 0.5 × [(Kd + EC50)/EC50] × (Emax/Bmax) (4). IC50 values for GnRH were used as an approximation of Kd.

**RESULTS**

**H2 Mutants Are Not Expressed, but Expression Is Restored in H2/H7 Reciprocal Mutant**—The effects of amino acid substitutions at each locus of the H2/H7 microdomain were studied. The substitutions introduced for Asn2.50(87) (Gln, Asp, and Ala) were designed to test the effects of altered size, charge, and polarity on receptor function. None of the single H2 mutant constructs studied exhibited detectable ligand binding activity, IP accumulation, or ARF-dependent accumulation of phosphatidyl butanol (PtdBut) (Table I).

To determine whether the lack of ligand binding by the H2 mutants resulted from altered receptor expression, we utilized an immunoblot assay of epitope-tagged receptor constructs. The parent epitope-tagged construct had an amino-terminal HA-tag and a carboxyl-terminal domain with a hexahistidine tag (see “Experimental Procedures”). The effects of epitope tagging on receptor function were evaluated. All H2 and H7 mutant constructs were epitope-tagged and tested in ligand binding and IP accumulation assays. The tagged wild-type and mutant receptors mediated IP accumulation with EC50 values which were comparable to those of corresponding untagged receptors. For all constructs with measurable ligand binding, Kd values were unchanged and Bmax values elevated with epitope tagging. As was observed for the untagged receptors, ligand binding was not detectable in the epitope-tagged N2.50(87)D and N2.50(87)A constructs (Table II). The epitope-tagged N2.50(87)Q construct exhibited low, but measurable ligand binding (Table II). This tagged construct also mediated a low level of GnRH-stimulated IP accumulation (not shown). The relative receptor expression, as measured by ligand binding, and the function of the tagged receptors closely paralleled that of the untagged receptors, thus validating the use of the tagged receptors in protein expression assays.
Multiple Functions of Helix 2 and 7 Microdomain

and coupling of these constructs is associated with very low levels of receptor protein.

In contrast to the results obtained with single H2 mutants, the reciprocal mutant, N2.50(87)D/D7.49(318)N, exhibited ligand binding (Table I), as described previously (8). In addition, this receptor was also clearly visible on immunoblot analysis, yielding a band which had lower intensity than that of the wild-type receptor (Fig. 1).

**Differing Expression of H7 Mutants**—The functions of GnRH receptors with Asp7.49(318) mutated to Asn, Glu, and Ala were transferred to nitrocellulose membrane as described under “Experimental Procedures.” Cell were transfected with epitope-tagged receptor constructs as described under “Experimental Procedures.” Cell were transfected with epitope-tagged wild-type and mutant GnRH receptors as described under “Experimental Procedures.”

*Fig. 1. Immunoblot of GnRH receptor constructs.* COS-1 cells were transfected with epitope-tagged wild-type and mutant GnRH receptor constructs as described under “Experimental Procedures.” Cell membranes were solubilized, deglycosylated, electrophoresed, and transferred to nitrocellulose membrane as described. Epitope-tagged receptors were detected with an antibody generated against tetrahistidine.

*Fig. 2. 125I-GnRH-A competition binding.* COS-1 cells were transfected with wild-type GnRH receptor (●) or mutant constructs D7.49(318)N (○), D7.49(318)E (▲), D7.49(318)A (■), D7.49(318)L (▼), and N2.50(87)D/D7.49(318)N (▼) and incubated with 125I-GnRH-A and increasing concentrations of unlabeled GnRH-A as described under “Experimental Procedures.” Data are the mean ± S.E. of a representative experiment performed in triplicate.

The functions of GnRH receptors with Asp7.49(318) mutated to Asn, Glu, and Ala were studied to evaluate the role of size, hydrogen bonding, and ionic interactions at this locus. All of these H7 mutants bound GnRH-A with affinities similar to that of the wild-type receptor (Fig. 2, Table I). The maximal binding of these constructs varied, with Asp (wild-type) ≥ Ala > Asn > Glu (Table I, Fig. 2). Immunoblot detection of the epitope-tagged H7 mutants correlated with the expression levels measured by ligand binding (Fig. 1). The high expression of the Ala, Asn, and Glu mutants shows that the negative charge and hydrogen bonding functions of the Asp side chain are not critical for efficient receptor expression. In contrast, the D7.49(318)E mutant, which conserves the carboxylate functional group, had greatly reduced expression, both by binding (5.2% of wild-type, Table I) and by immunoblot (Fig. 1). These results indicate that the H7 interaction imposes specific steric constraints that are optimal for Asp and are only poorly matched by a negatively charged side chain of a larger size. To test whether the low expression of the Glu mutant was due to poor tolerance of the larger bulk of the Glu side chain, or to misalignment of the carboxyl group, Asp7.49(318) was substituted with Leu. The low expression of the D7.49(318)L mutant relative to the D7.49(318)A construct (Table I, Figs. 1 and 2) suggests that the reduced expression of the D7.49(318)E receptor results from the increase in bulk of the side chain and not from altered positioning of the carboxyl group.

**H1 Mutants Are Not Expressed, and the H1/H7 Reciprocal Mutant Does Not Restore Expression**—The high expression of the non-polar H7 mutant, Ala7.49(318), shows that the low expression of the H2 mutants is not due to loss of an interaction with the H7 side chain. It has been proposed, for other GPCRs, that the 2.50 side chain interacts with the highly conserved Asn1.50 side chain in H1 (10, 18). To test whether the low expression of the H2 mutants might be due to disruption of an interaction with Asn1.50(53) in the GnRH receptor, this residue was mutated to Asp, Ala, and Leu. All H1 mutant constructs exhibited no measurable ligand binding or GnRH-stimulated accumulation of IP (Table I) and yielded only faintly detectable bands on immunoblots (Fig. 1). A reciprocal mutant, N1.50(53)D/D7.49(318)N, was constructed to test whether the locus 7.49 side chain influences the function of the Asn1.50(53) side chain. This reciprocal mutant showed no recovery of the ligand binding and IP accumulation which is lost in the H1, N1.50(53)D single mutant (Table I).

**Phospholipase C (PLC) Activation**—While all of the H7 mutants (except for Leu7.49(318)) were capable of mediating GnRH-stimulated IP production, the EC50 values were increased and Emax values decreased in comparison with the wild-type GnRH receptor (Fig. 3A, Table I). The magnitude of IP stimulation observed did not correlate with levels of mutant receptor expression. For example, the D7.49(318)A construct, which expressed at wild-type levels, exhibited low maximal IP response (12% of wild-type Emax). In contrast, the poorly expressed D7.49(318)E mutant showed a relatively high IP signal (36.6% of wild-type Emax). These results reveal distinct side chain requirements for expression and for coupling to PLC.

An empirical measure of receptor coupling efficiency that estimates the functional response achieved per agonist-occupied receptor was calculated for each construct, as described previously (4) (see “Experimental Procedures”). The rank order of coupling efficiency for PLC was: wild-type, Asp > Glu > Asn > reciprocal H2D/H7N > Ala (Fig. 3B, Table I). It was not possible to calculate coupling efficiency for the D7.49(318)L mutant because of its lack of measurable binding and IP accumulation. The low efficiency of the Ala and Asn mutants indicates the importance of the polar and ionic functions of the native Asp side chain in PLC coupling. However, the high efficiency of the D7.49(318)E construct shows that a carboxylate side chain is required for efficient coupling to PLC.

It is notable that the PLC coupling efficiency of the reciprocal mutant (with Asp in H2, Asn in H7) was lower than for the D7.49(318)N single mutant (Table I, Fig. 3B). In other PLC-coupled GPCRs, mutants containing Asn residues at both the 2.50 and 7.49 loci were poorly coupled (9, 10), a result which we also see in the GnRH receptor (Table I). However, in contrast to the other GPCRs studied, where reciprocal mutation restored coupling (9, 10), the GnRH receptor appears unique in that the poor coupling persists with the interchange mutations. These commonalities and differences have implications for understanding the patterns of intramolecular signal transduction associated with GnRH receptor activation (see “Discussion”). They may also represent the special properties or importance of an Asp side chain in H7 in the GnRH receptor (18), which is present in the wild-type receptor in species from bony fish to mammals.

**PLD Activation**—We have recently reported that the BFA-sensitive component of PLD activation depends on receptor interaction with small G proteins in the ARF/RhoA family (19).
was measured in COS-1 cells transfected with wild-type (●) receptor constructs. Transfected cells were stimulated with GnRH (1 μM) in the presence of increasing concentrations of the ARF inhibitor, BFA. Data are the mean ± S.E. of four to ten experiments performed in duplicate.

GnRH was found to stimulate PtdBut accumulation via the wild-type receptor and all of the H7 mutants (Fig. 4, Table I). However, only the response mediated by the D7.49(318)N mutant and the N2.50(87)D/D7.49(318)N reciprocal mutant exhibited the BFA sensitivity characteristic of coupling to the small G protein, ARF (Fig. 4, Table I). Thus, in contrast to heterotrimERIC G-protein coupling, coupling to ARF appears to have a stringent requirement for an Asn residue at position 7.49. This requirement may relate to stabilization of different activated receptor conformations when the side chain at this position is varied (see "Discussion").

DISCUSSION

The H2/H7 microdomain of the GnRH receptor is unusual among GPCRs in having an Asn residue at position 2.50(87).

Our study of the role of each side chain of the microdomain in distinct GnRH receptor functions supports the importance of this structural microdomain and reveals the elements of the microdomain that are necessary for each function. The Asn in H2 is required for stable receptor expression and the Asp in H7 is critical both for efficient coupling to PLC and for excluding ARF-dependent coupling to PLD.

Requirement for Asn$^{2.50(87)}$ in Receptor Expression—All mutations of the Asn residue in H2 profoundly disrupted receptor expression. This resulted in a loss of signal in ligand binding assays, second messenger determination, and immunoblot analysis. The immunoblot results indicate that the loss of receptor-binding sites for the H2 mutants most likely results from a decrease in membrane receptor protein. Mutations that led to intracellular retention of receptor (29) and receptor protein instability (30) have been reported for the β-adrenergic receptor. Thus, the loss of GnRH receptors with mutations of H2 could be due either to disruption of biosynthesis and trafficking to the membrane or to instability and degradation of the expressed receptor.

The requirement for an Asn$^{2.50(87)}$ residue in H2 for expression is an unusual feature of the GnRH receptor. Furthermore, the detrimental effect of the simultaneous presence of Asp at both the 2.50 and 7.49 loci on receptor expression is not observed in most other GPCRs studied (9, 10, 12, 17, 31). Incorporation of a second Asp residue in the H2/H7 microdomain, by mutating the Asn7.49 residue to Asp in the 5-HT2A, TRH, cholecystokinin B (CCKb), and NK2 receptors, which have Asp at position 2.50, caused relatively modest decreases in receptor $B_{max}$ levels (9, 10, 12, 14). Only the μ-opioid receptor is similar to the GnRH receptor in manifesting complete loss of binding with Asp present at both the H2 and H7 loci (11). The ability of some GPCRs to tolerate Asp side chains at both loci has led some workers to conclude that the H2 and H7 side chains are unlikely to be in close proximity (14). However, crystallographic studies reveal that Asp side chains can occur in close proximity within proteins and can form hydrogen bonds when one of the Asp side chains is protonated (32, 33). Thus, the tolerance of Asp residues at both loci in various GPCRs does not exclude proximity of the side chains of the H2/H7 microdomain. Differences in the complement of amino acids that constitute the microenvironment of this domain in different receptors most likely determine the specific side chains that are tolerated at each position. The present results and data from all other GPCRs studied are consonant with spatial proximity of the conserved H2 and H7 side chains.

In view of the profound decrease in expression observed with substitutions for Asn$^{2.50(87)}$, it is difficult to draw firm conclusions from mutagenesis studies about the role of this side chain in receptor coupling. The detection of some receptor function with the epitope-tagged N2.50(87)Q mutant suggests that preserving a polar amide side chain at this position may preserve receptor function to a greater extent than the other substitutions tested. While a role of Asn$^{7.49(87)}$ in receptor activation cannot be inferred from the present data, such a role would be consistent with previously reported computational studies which suggest that both Asp$^{2.50(87)}$ and Asp$^{7.49(87)}$ interact with the conserved Arg$^{3.50(139)}$ side chain to stabilize the active state of the receptor (4).

H7 Side Chain at the 7.49 Locus Is Not Required for Receptor Expression—We have demonstrated that restoration of GnRH receptor binding with the reciprocal mutation, N2.50(87)D/D7.49(318)N, is accompanied by restoration of receptor expression, as determined by immunoblotting. These results suggest that the strict requirement for Asn in position 2.50 can be satisfied by insertion of an amide side chain in the spatially...
adjacent 7.49 locus. Alternatively, a charged Asp side chain can substitute for the Asn\textsuperscript{2.50} residue in the GnRH receptor when a destabilizing interaction with the H7 side chain is removed by substitution of the charged Asp\textsuperscript{7.49} residue with an uncharged Asn residue. The relatively high expression of the D7.49(318)A mutant indicates that a direct interaction between the 2.50 and 7.49 side chains is not required for receptor expression. This mutant was the best expressed of the mutant receptors in this study, but since the side chain of Ala is non-polar, it cannot form a hydrogen bond with the residue in position 2.50. It has been proposed that the Asp\textsuperscript{2.50} side chain of the TRH receptor forms hydrogen bonds with both the Asn\textsuperscript{7.49} side chain and the highly conserved Asn\textsuperscript{1.50} side chain in H1 (10). The Asn\textsuperscript{1.50} residue is conserved in the GnRH receptor and, based on computational modeling (4, 8), could interact with the Asn\textsuperscript{2.50} side chain. Our results showing that an interaction with Asp\textsuperscript{7.49} is not required for expression of the GnRH receptor, suggested that an interaction between the side chains of Asn\textsuperscript{2.50} and Asn\textsuperscript{1.50} may be required for stable receptor expression. Mutation of Asn\textsuperscript{1.50} to Ala, Asp, or Leu also yielded constructs with very low expression, similar to the H2 mutants. The similar phenotypes of mutants with subtle changes in H1 or H2 is consistent with, and supports a role for a hydrophilic interaction between these side chains in stabilizing expression of the GnRH receptor. A reciprocal mutant, N1.50(53)/D7.49(318)N, did not recover the function lost in the H1 mutants, showing that the H7 side chain does not influence the function of the H1 side chain in the same way as it does the H2 side chain. This is consistent with molecular models which show polar interactions of the 2.50 side chain with the 1.50 and 7.49 side chains, but no direct interaction between the 1.50 and 7.49 loci (7, 10, 18, 34).

The high levels of expression observed with mutations of the Asp\textsuperscript{7.49} to either Asn or Ala indicate that the functional features of the Asp side chain are not required for efficient receptor expression. In fact, the H7 mutant which preserves the acidic group, D7.49(318)E, had much lower expression than receptors with Ala or Asn substitutions at this position. These data reveal that expression is sensitive to the length of the negatively charged side chain at position 7.49. These results suggest that a larger side chain at position 7.49 may interfere with receptor assembly, either through steric interference that would disrupt helix packing due to increased bulk of the side chain, or through a disruption of protein folding by misalignment of the carboxyl group. To determine whether the detrimental effect of the Glu\textsuperscript{7.49} mutation on receptor function was due to the increased bulk of the side chain or to unfavorable positioning of the carboxyl group, Asp\textsuperscript{7.49} was mutated to Leu. The low expression of this mutant indicates that the receptor cannot accommodate a bulky side chain in this position.

Acidic Side Chain Required at Locus 7.49 for Efficient Activation of PLC—In contrast to the poor expression seen with the mutation of Asp\textsuperscript{7.49} to Glu, the PLC coupling efficiency of this mutant is comparable to that of the wild-type receptor (Table I, Fig. 3B). In contrast, the D7.49(318)A mutant was well expressed and yet was nearly uncoupled from PLC activation (Table I, Fig. 3). The preservation of the PLC coupling efficiency of the D7.49(318)E mutant, which conserves the negative charge of the Asp side chain, indicates that a carboxylate side chain is necessary for efficient activation of heterotrimeric G proteins. The rank order of the coupling efficiency of mutants with H7 side chain substitutions, Asp > Glu > Asn > Ala, is consistent with the involvement of ionic and hydrogen bonds in the interactions of these side chains with the highly conserved Arg\textsuperscript{3.50} residue. These data are consistent with our proposal that an interaction between the Arg\textsuperscript{3.50} and Asp\textsuperscript{7.49} side chains stabilizes receptor activation (4).

The amino acid side chains in the H2/H7 microdomain of the GnRH receptor that are required for efficient coupling to heterotrimeric G proteins differ from those required in other GPCRs. In GPCRs which have the canonical wild-type Asp-Asn arrangement of the microdomain, the Asp\textsuperscript{7.49} side chain is required for efficient G protein coupling (9, 10, 12, 14, 31). In addition, a polar residue is required in H7. Mutation of Asn\textsuperscript{7.49} to Ala significantly uncoupled the \( \beta \)-adrenergic, angiotensin AT1, serotonin 5-HT\textsubscript{2A}, TRH, and NK\textsubscript{2} tachykinin receptors (9, 10, 12, 17, 35). However, mutation of Asn\textsuperscript{7.49} to Asp had minimal effects on the coupling of the \( \beta \)-adrenergic, serotonin 5-HT\textsubscript{2A}, TRH, CCK\textsubscript{b}, and NK\textsubscript{2} receptors (9, 10, 12, 14, 17). The ability of Asp, but not Ala, to substitute for the conserved Asn\textsuperscript{7.49} residue suggests that hydrogen bonding interactions of Asn\textsuperscript{7.49} may be required for efficient coupling of these receptors. Thus, single site mutation experiments show that activation of these GPCRs requires an acidic (Asp) residue in position 2.50 and a polar residue (Asn or Asp) in the 7.49 locus. Reciprocal mutation of this microdomain in the 5-HT\textsubscript{2A}, TRH, \( \mu \)-opioid, and NK\textsubscript{2} receptors has shown that moving the Asp side chain from H2 to H7 results in a significant recovery of the uncoupling which results from the loss of the Asp side chain at position 2.50 (9–12). Thus, for many GPCRs, the presence of an Asp in the H2/H7 microdomain is required for efficient coupling, but the Asp may be located at either position 2.50 or 7.49.

In the GnRH receptor, single mutations of Asp\textsuperscript{7.49} show that this receptor also requires an acidic residue for coupling to PLC (Table I, Fig. 3). However, unlike the other GPCRs, the movement of the Asp side chain within the microdomain (from H7 to H2 in the double mutant) does not preserve efficient PLC coupling. Thus, in the GnRH receptor, the Asp residue which is required for efficient coupling appears to have been transferred from H2 to H7 in comparison with other GPCRs. Furthermore, the GnRH receptor has fixed the requirement for the acidic side chain at the H7 locus. The structural basis for these unique features of the GnRH receptor may be determined by the various non-conserved side chains that contribute to the environment of the H2/H7 microdomain, including the special properties of the H7 structure which, in the GnRH receptor, has 2 NP/DP motifs (18).

The non-mammalian GnRH receptors have Asp residues in both the H2 and H7 loci (15, 16). The presence of the two Asp residues in these receptors raises the possibility that the non-mammalian GnRH receptors represent evolutionary intermediates between the conserved Asp-Asn arrangement found in most GPCRs and the Asn-Asp arrangement found in all mammalian GnRH receptors (1). Like the mammalian GnRH receptor, the non-mammalian, catfish receptor exhibited decreased coupling when the Asp residue in H7 was mutated to Asn (15). As in the present study, lack of ligand binding activity prevented analysis of H2 mutants of the catfish GnRH receptor (15), so it is not possible to determine whether the carboxylate function of the H2 Asp side chain is required for coupling of the non-mammalian GnRH receptor. In contrast, the platelet activating factor receptor, which also has Asp residues at both loci, retained coupling to PLC when the H7 Asp residue was mutated, but was uncoupled when the H2 Asp residue was mutated (36), showing that this receptor retains its Asp residue coupling function in H2.

Asp\textsuperscript{7.49} Required for ARF-mediated Activation of PLD—Computational simulations of agonist binding to the wild-type and D2.50N mutant serotonin 5HT\textsubscript{2A} receptors showed that agonist binding induces a conformational rearrangement of the mutant receptor which is different from the agonist-induced
conformation of the wild-type receptor (9). This suggests that mutant GPCRs that do not have an Asp residue in the H2/H7 microdomain are able to assume an activated conformation, but that this conformation is different from the activated conformation of the wild-type receptors that have an Asp residue in this microdomain. Mutation of the Asp2.50 side chain has variable effects on signal transduction in different receptors (9, 31). Mutating the Asp2.50 residue of the αα-adrenergic receptor had differential effects on different signal transduction pathways. The D2.50N mutant αα-adrenergic receptor retained the ability to mediate inhibition of adenyl cyclase and calcium currents, but could not achieve the conformation necessary for activation of the distinct G proteins that mediate activation of potassium channels (37).

The GnRH receptor mutants which lack an acidic residue in the H2/H7 microdomain were poorly coupled to activation of PLC. In contrast, the D7.49N/D7.49N mutant gained the capacity to mediate ARF-dependent activation of PLD (Table I, Fig. 4). Furthermore, as previously demonstrated, the reciprocal mutant (N2.50N/D7.49N) also shows a pattern of PtdBut accumulation characteristic of ARF-dependent signaling (19). This shows that the presence of a carboxylate side chain in the 7.49 locus is necessary for efficient ARF-mediated coupling to PLD (19). This shows that the capacity to assume a conformation for coupling to ARF is conserved across different receptors.

We gratefully acknowledge Drs. Frank Guarnieri and Juan Ballesteros for many helpful discussions.

REFERENCES

1. Sealfon, S. C., Weinstein, H., and Millar, R. P. (1997) Endocr. Rev. 18, 180–205
2. Baldwin, J. M. (1993) EMBO J. 12, 1635–1703
3. Probst, W. C., Snyder, L. A., Schuster, D. I., Brosius, J., and Sealfon, S. C. (1992) DNA Cell Biol. 11, 1–20
4. Ballesteros, J., Kitanovic, S., Guarnieri, F., Davies, P., Fromme, B. J., Konvicka, K., Shi, L., Millar, R. P., Davidson, J. S., Weinstein, H., and Sealfon, S. C. (1998) J. Biol. Chem. 273, 10445–10453
5. Schertler, G. F., Villa, C., and Henderson, K. (1993) Nature 362, 770–772
6. Schertler, G. F., and Hargrave, P. A. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 11571–11572
7. Ballesteros, J., and Weinstein, W. (1995) Methods Neurosci. 25, 366–428
8. Zhou, W., Flanagan, C., Ballesteros, J. A., Konvicka, K., Davidson, J. S., Weinstein, H., Millar, R. P., and Sealfon, S. C. (1994) Mol. Pharmacol. 45, 165–170
9. Sealfon, S. C., Shi, L., Ebersole, B. J., Rodie, V., Zhang, D., Ballesteros, J. A., and Weinstein, W. (1995) J. Biol. Chem. 270, 16853–16858
10. Perlman, J. H., Colson, A.-O., Wang, W., Bence, K., Osman, R., and Gershengorn, M. C. (1997) J. Biol. Chem. 272, 11937–11942
11. Xu, W., Ondrizer, F., Li, J., Chen, C., de Riel, J., Weinstein, H., and Liu-Chen, L. (1997) FEBS Lett. 447, 318–324
12. Donnelly, D., Maude, S., Gent, J. P., Hos, R. N., Hurrell, C. R., and Boogaerts, B. (1995) Mol. Pharmacol. 48, 783–789
13. Cook, J. V., Facenda, E., Anderson, L., Cooper, G. G., Eisde, K. A., and Taylor, P. L. (1993) J. Endocrinol. 139, 81–4
14. Jagerschmidt, A., Guillaume, N., Goudreau, N., Maigret, B., and Roques, B. (1995) Mol. Pharmacol. 28886
15. Ilting, N., Troskie, B., Nahraniak, C., Haggouj, J., Peter, R., and Millar, R. (1990) Proc. Natl. Acad. Sci. U. S. A. 96, 2526–2531
16. Barak, I., Lenard, I., Ferguson, S. S., Colapietro, A. M., and Caron, M. G. (1995) Biochemistry 34, 15407–15414
17. Konvicka, K., Guarnieri, F., Ballesteros, J., and Weinstein, H. (1998) Biophysics J. 75, 601–611
18. Mitchell, R., McCulloch, D., Lutz, E., Johnson, M., MacKenzie, C., Fennell, M., Fink, G., Zhou, W., and Sealfon, S. (1998) Nature 392, 411–414
19. Millar, R., Conklin, D., Lofton-Day, C., Hutchinson, E., Troskie, B., Ilting, N., Sealfon, S. C., and Haggouj, J. (1999) J. Endocrinol. 162, 117–126
20. Zhou, W., Rodie, V., Kitanovic, S., Flanagan, C. A., Shi, L., Weinstein, H., Maayani, S., Millar, R. P., and Sealfon, S. C. (1996) J. Biol. Chem. 270, 18853–18857
21. Laws, S. C., Beggs, M. J., Webster, J. C., and Miller, W. L. (1995) Endocrinology 127, 373–380
22. Sealfon, S., Zhou, W., Alama, L., and Rodie, V. (1996) Methods Neurosci. 29, 143–196
23. Millar, R. P., Davidson, J., Flanagan, C. A., and Wakefield, I. (1995) Methods in Neurosciences, Receptor Molecular Biology, pp. 145–162, Academic Press, San Diego
24. Berg, K. A., Clarke, W. P., Saltman, C., Baldwin, J. A., and Fennell, M. (1995) Biophysics J. 53, 2085–2090
25. Munson, P. J., and Rodbard, D. (1980) Anal. Biochem. 107, 220–239
26. Davidson, J. S., Assefa, D., Terszoi, A., Davies, V., Haggouj, J., Becker, L., Flanagan, C., Roesske, R., and Millar, R. (1997) Biochemistry 36, 12881–12889
27. Suryanarayana, S., Swant, R. K., and Hapgood, J., and Kubik, B. K. (1991) J. Biol. Chem. 266, 15454–15459
28. Gether, U., Ballesteros, J. A., Seifert, R., Sanders-Bush, E., Weinstein, H., and Kubik, B. K. (1997) J. Biol. Chem. 272, 2587–2590
29. van Riet, A. M., and Jacobson, R. A. (1996) Drug Dev. Res. 37, 1–28
30. Davies, R. D. (1990) Annu. Rev. Biophys. Biophys. Chem. 19, 289–304
31. Scheer, A., Fanelli, F., Costa, T., and Cotecchia, S. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 808–813
32. Hunyady, L., Balla, A., and Catt, K. J. (1995) J. Biol. Chem. 270, 16602–16609
33. Parment, J.-L., Le Gouill, C., and Ehrlich, W., Plaszenzy, M., and Stakova, J. (1996) J. Biol. Chem. 271, 23288–23303
34. Surprenant, A., Horstman, D. A., Akbarali, H., and Limbird, L. E. (1992) Science 257, 977–980

K. Konvicka and H. Weinstein, unpublished results.